Jupiter Neurosciences Selected as B2i Digital Featured Company Amid Parkinson's Trial Progress and Longevity Brand Expansion

Jupiter Neurosciences, Inc. has been selected as a B2i Digital Featured Company, a designation that highlights the clinical-stage pharmaceutical company's progress in advancing neuroinflammation treatments and its dual-path business strategy. The company is currently conducting an FDA-cleared Phase IIa clinical trial in Parkinson's disease, with additional exploration in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. These research efforts are supported by collaborations with several prestigious institutions including Harvard University, Georgetown University, MIT's Picower Institute, and the University of Miami.

Alongside its clinical development pipeline, Jupiter Neurosciences is expanding Nugevia™, a consumer longevity brand powered by its proprietary JOTROL™ enhanced resveratrol formulation. This dual-path approach combines traditional pharmaceutical development with emerging commercial revenue streams, creating what company leadership describes as a differentiated operating model. The strategy allows Jupiter to advance its clinical programs while simultaneously building potential revenue pathways through its consumer products.

David Shapiro, Chief Executive Officer of B2i Digital, emphasized the investment opportunity presented by Jupiter's approach. "Jupiter Neurosciences offers investors a differentiated opportunity within the CNS sector," Shapiro stated. "With a Phase IIa Parkinson's trial underway and a consumer longevity platform already in market, the company is advancing its pipeline while building potential revenue streams." The B2i Digital platform serves growth-stage public companies by helping management teams sharpen their capital markets narrative and engage directly with active investors across the investor conference ecosystem.

Christer Rosén, Founder, Chairman and CEO of Jupiter Neurosciences, characterized this period as a significant inflection point for the company. "As our Parkinson's program progresses and Nugevia continues to scale, partnering with B2i Digital strengthens our ability to communicate our story to the broader capital markets," Rosén explained. The company's therapeutic pipeline targets central nervous system disorders and rare diseases, while its consumer products bring clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function.

The selection as a B2i Digital Featured Company provides Jupiter Neurosciences with enhanced visibility across B2i Digital's investor network, which includes more than 1.5 million capital markets participants and a curated email distribution of more than 100,000 investors and industry professionals. This increased exposure comes at a critical time as the company advances its Parkinson's disease trial and expands its consumer brand presence. More information about Jupiter Neurosciences can be found at https://www.jupiterneurosciences.com, while details about B2i Digital are available at https://b2idigital.com.